Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis

Phase 2 Completed 202 enrolled Swiss Tropical & Public Health Institute National Institute of Public Health, Vientiane, Laos · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

Efficacy, safety and pharmacokinetics of ascending dosages of emodepside and in comparison to ivermectin against Strongyloidiasis stercoralis in adults: randomized stage II seamless adaptive controlled trials

Timeline

Start: 2024-05-20
Primary completion: 2024-09-21
Completion: 2024-09-21

Publications

Taylor L, Many S, Jeanguenat H, Hattendorf J, Sayasone S, Keiser J. Efficacy and safety of ascending doses of emodepside in comparison with ivermectin in adults infected with Strongyloides stercoralis in Laos: a phase 2a, dose-ranging, randomised, parallel-group, placebo-controlled, single-blind clinical trial. Lancet Infect Dis. 2025 Nov;25(11):1254-1264. doi: 10.1016/S1473-3099(25)00255-5. Epub 2025 Jun 25.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Emodepside	Small molecule	5 mg	Oral
Subject	Emodepside	Small molecule	10 mg	Oral
Subject	Emodepside	Small molecule	15 mg	Oral
Subject	Emodepside	Small molecule	20 mg	Oral
Subject	Emodepside	Small molecule	25 mg	Oral
Subject	Emodepside	Small molecule	30 mg	Oral
Subject	Ivermectin	Small molecule	3 mg	Oral

Efficacy and Safety of Emodepside in Adults Infected With Strongyloidiasis Stercoralis

Summary

Timeline

Publications

Drugs

Indications